ArticleEJIFCC2025
Practices and Insights for Diabetes Mellitus Testing in Sri Lanka, Singapore and the Philippines.
Article in EJIFCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Considering The pivotal role of biochemical testing for the management of diabetes mellitus, we studied the current status of diabetes testing and reporting in three countries of the Asia-Pacific region. Methods: A survey of 254 practicing pathology laboratories comprising of 40, 11 and 203 laboratories from Sri Lanka, Singapore and the Philippines was conducted under the auspices of the Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB) Working Group for Diabetes Testing Harmonization using Survey Monkey and Google Forms. Results: The country response rate varied from 40% to 88%. A diagnostic threshold of 6.5% (48 mmol/mol) for HbA1c is reported by 51%, 22% and 90% of the participant laboratories in Sri Lanka, Singapore and the Philippines, respectively. All participants in Singapore and 86% of the laboratories in Philippines use NGSP-certified methods for HbA1c. Traceability to Certified Reference Materials for both glucose and HbA1c results was confirmed by 74% of Sri Lankan laboratories. For albuminuria testing, early morning spot urine albumin to creatinine ratio is recommended by 56%, 75% and 69% of the laboratories in Sri Lanka, Singapore and the Philippines, respectively, while 16%, 50% and 26% of the laboratories recommended 24-hour urine collection. Conclusion: There is a lack of harmonization in diabetes testing and reporting practices both across and even within the three countries surveyed. Scientific bodies or professional associations have an important role in harmonization of laboratory testing and reporting of results for the diagnosis and management of diabetes mellitus.
Indexed as
Identifiers
40061062PMC11886627What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.